explore -WSS

explore

author：leisure time 2025-09-06 08:24:56 - browse：85781

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： FDA approves updated Covid vaccines

leisure time

WSS

ALS advocates say criticism of new drugs misses bigger picture

Generate Biomedicines machine learning biotech raises $273M

Regeneron agrees to White House price limits on anti

Pig kidney works a record two months in donated body

FDA approves updated Covid vaccines

AstraZeneca chief proposes a novel edit to the drug pricing bill

focus

explore

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Food makers tried to stack nutrition panel with preferred experts

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA approves updated Covid vaccines

Continuity nursing helped my family in our darkest PICU moments

IRA could hurt research into orphan drugs for rare diseases

Medical leaders decry Supreme Court decision on affirmative action

How to protect patients from sexual assault

New air purifier tech could be key to improving indoor air quality

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

explore

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

NIH nominee Bertagnolli will get October confirmation hearing

Illumina names Agilent executive as new CEO

Stem cell treatment guidelines are released by FDA

Telehealth for opioid use disorder is lifesaving

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

focus

leisure time

leisure time

leisure time